RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Thanigaivelan Kanagasabai to Xenograft Model Antitumor Assays

Back to Details
This is a "connection" page, showing publications Thanigaivelan Kanagasabai has written about Xenograft Model Antitumor Assays.
Thanigaivelan Kanagasabai
Connection Strength
0.186
Xenograft Model Antitumor Assays
  1. Rathinavelu A, Alhazzani K, Dhandayuthapani S, Kanagasabai T. Anti-cancer effects of F16: A novel vascular endothelial growth factor receptor-specific inhibitor. Tumour Biol. 2017 Nov; 39(11):1010428317726841.
    View in: PubMed
    Score: 0.142
  2. Tewary P, Brooks AD, Xu YM, Wijeratne EMK, Babyak AL, Back TC, Chari R, Evans CN, Henrich CJ, Meyer TJ, Edmondson EF, de Aquino MTP, Kanagasabai T, Shanker A, Gunatilaka AAL, Sayers TJ. Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins. Cancer Res. 2021 06 15; 81(12):3374-3386.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support